Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the 36th World Congress of Audiology (WCA), taking place in Paris, France, on September 19-22, 2024.

On this occasion, Sensorion will host a symposium on September 20, 2024, at 12.30pm CET, entitled:

“Are we at the Dawn of a Hearing Loss Revolution?”

This event will be hosted by Professor Natalie Loundon ENT Surgeon in the pediatric Hospital Necker-Enfants malades in Paris, France. The symposium will comprise three sessions:

  • 1st Session: Hearing Preservation: Relevant Medical Progress in Cisplatin-Induced Ototoxicity and the Loss of the Residual Hearing following Cochlear Implantation

This session will focus on the therapeutic advances in hearing preservation associated with Cisplatin-Induced Ototoxicity and following cochlear implantation. Professor Yann Nguyen (ENT Surgeon, Hôpital de la Pitié Salpêtrière, Paris, France) and Professor Stephen O'Leary (Head of Otolaryngology at the University of Melbourne, Melbourne, Australia) will co-present this session.

  • 2nd Session: Gene therapy: A Ray of Hope for Congenital Hearing Disorders

This session will address gene therapy applied to patients suffering from congenital profound deafness and will be presented by Professor Catherine Birman (Otorhinolaryngologist, Director of the Sydney Cochlear Implant Centre, Sydney, Australia).

  • 3rd Session: Conclusion: What Does the Future Hold for these New Therapies?

This session will be led by Professor Natalie Loundon (Pediatric otorhinolaryngologist, Director of the Cochlear Implant and Audiology Unit, Necker-Enfants malades, Paris, France) and will address the impact these new therapies will have on patient management, followed by a question-and-answer session.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Label: SENSORION ISIN: FR0012596468 Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Investor Relations Noémie Djokovic, Chargée des Relations Investisseurs et de la Communication ir.contact@sensorion-pharma.com

Press Relations Ulysse Communication Bruno Arabian / 00 33(0)6 87 88 47 26 barabian@ulysse-communication.com Nicolas Entz / 00 33 (0)6 33 67 31 54 nentz@ulysse-communication.com

Sensorion (EU:ALSEN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Sensorion Charts.
Sensorion (EU:ALSEN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Sensorion Charts.